Volume 1.09 | Mar 16

Hematopoiesis News 1.09, March 16, 2010.  
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe


CCR2 Mediates Hematopoietic Stem and Progenitor Cell Trafficking to Sites of Inflammation in Mice
As monocytes are recruited to sites of inflammation via chemoattractants that activate CCR2 on their surface, researchers investigated whether hematopoietic stem cells are also recruited to sites of inflammation through CCR2. [J Clin Invest]

MethoCult® Express Video  
Learn about the benefits of MethoCult® Express
for cord blood samples

by STEMCELL Technologies


Scots Close to Medicine’s Holy Grail, A True Blood Substitute
Scientists are reporting that a three-year, multi-million pound Scottish National Blood Transfusion Service project is on course to reach its ambitious target of creating a limitless, long lasting, virus-free artificial blood supply. [HeraldScotland Press Release]




Tumor Stroma-Derived TGF-Beta Limits Myc-Driven Lymphomagenesis Via Suv39h1-Dependent Senescence
Using the E??-myc transgenic mouse lymphoma model, researchers show in vivo that apoptotic lymphoma cells activate macrophages to secrete transforming growth factor-beta as a critical non-cell-autonomous inducer of cellular senescence. [Cancer Cell]

Homeodomain-Interacting Protein Kinase 2 Plays an Important Role in Normal Terminal Erythroid Differentiation
Homeodomain-interacting protein kinases 2 (Hipk2) knockdown also reduces the transcription of many genes involved in proliferation and apoptosis as well as important, erythroid-specific genes involved in hemoglobin biosynthesis, such as alpha-globin and mitoferrin 1, demonstrating that Hipk2 plays an important role in some but not all aspects of normal terminal erythroid differentiation. [Blood]

Genome-Wide Homozygosity Signatures and Childhood Acute Lymphoblastic Leukemia Risk
The findings make it unlikely that levels of measured homozygosity, caused by autozygosity, uniparental isodisomy or hemizygosity play a major role in defining B-cell precursor acute lymphoblastic leukemia risk in predominantly outbred populations. [Blood]

Pharmacologic Modulation of Niche Accessibility Via Tyrosine Kinase Inhibition Enhances Marrow and Thymic Engraftment Following Hematopoietic Stem Cell Transplantation
Researchers studied whether sunitinib, a multi-tyrosine kinase inhibitor that inhibits KIT, enhances engraftment after bone marrow transplantation in mice. [Blood]

Deregulated Gene Expression Pathways in Myelodysplastic Syndrome Hematopoietic Stem Cells
To gain insight into the molecular pathogenesis of the myelodysplastic syndromes (MDS), researchers performed global gene expression profiling and pathway analysis on the hematopoietic stem cells (HSC) of 183 MDS patients as compared with the HSC of 17 healthy controls. [Leukemia]

Aberrant Expression of CD19 in Acute Myeloid Leukemia With t(8;21) Involves a Poised Chromatin Structure and PAX5
This study shows that expression of PAX5 in leukemic cells has functional consequences and points to an important role of a progenitor-specific chromatin configuration in myeloid leukemia. [Oncogene]

Imatinib Resistance Associated with BCR-ABL Upregulation is Dependent on HIF-1Alpha-Induced Metabolic Reprograming
In this study, researchers show that when BCR-ABL-transformed cell lines were selected for imatinib resistance in vitro, the cells that grew out displayed a higher BCR-ABL expression comparable to the increase seen in accelerated forms of the disease. [Oncogene]

Identification of a Panel of Ten Cell Surface Protein Antigens Associated With Immunotargeting of Leukemias and Lymphomas by Peripheral Blood Gamma-Delta T Cells
The results suggest that hematopoietic tumors display a highly variable repertoire of surface proteins that can impact on VgammaVdelta cell-mediated immunotargeting. [Haematologica]


Gene Expression-Based Classification As an Independent Predictor of Clinical Outcome in Juvenile Myelomonocytic Leukemia
Gene expression-based classification identifies two groups of patients with juvenile myelomonocytic leukemia with distinct prognosis outperforming all known clinical parameters in terms of prognostic relevance. [J Clin Oncol]

Evaluation of the (R)VAD+C Regimen for the Treatment of Newly Diagnosed Mantle Cell Lymphoma. Combined Results of Two Prospective Phase II Trials from the French GOELAMS Group
The (R)VAD+C (VAD associated with chlorambucil and rituximab) is an effective regimen with very low toxicity. In addition to the MIPI score, Ki67 expression provides additional independent prognostic information for the prediction of overall survival. [Haematologica]


Affymax(R) Receives $5 Million Milestone Payment on Initiation of Phase III Clinical Trials for Hematide(TM) in Japan
Affymax, Inc. announced that it has received a $5 million development milestone payment from Takeda Pharmaceutical Company as part of the companies’ exclusive global agreement to develop and commercialize Hematide(TM), Affymax’s investigational drug for the treatment of anemia in chronic renal failure patients. [Affymax, Inc. Press Release]

GlaxoSmithKline Receives Marketing Authorisation in the EU for Revolade® (eltrombopag)
GlaxoSmithKline confirmed that the European Commission has granted marketing authorisation for Revolade ® (eltrombopag) for the oral treatment of thrombocytopenia in adults with the blood disorder chronic immune thrombocytopenic purpura. [GlaxoSmithKline Press Release]

Start of Phase I/II Gene Therapy Clinical Trial for Hemophilia B
Amsterdam Molecular Therapeutics announced that the first patient has been dosed in the Phase I/II exploratory clinical trial with a gene therapy product for hemophilia B, a seriously debilitating and potentially lethal disease. [Amsterdam Molecular Therapeutics Press Release]

Completion of Aspirin Comparison Human Trial for Fruitflow
Provexis plc, which focuses on the discovery, development and licensing of scientifically-proven functional food, medical food and dietary supplement technologies, announced the completion of the human trial comparing the effects of its Fruitflow® anti-thrombotic technology with aspirin. [Provexis Plc. Press Release]


California Institute for Regenerative Medicine Allocates $50 Million for Stem Cell Therapy Development, a Boost for the State’s Growing Stem Cell Industry
In a move that will speed the path of bringing stem cell-based therapies to the people of California, the Governing Board of the California Institute for Regenerative Medicine, the state stem cell agency created by Proposition 71, approved a concept proposal for funding the development of new stem cell therapies. [California Institute for Regenerative Medicine, United States]

Government to Pour 5 Billion Yen into Induced Pluripotent Stem Cell Research
A government panel on science and technology picked 30 projects recently to be funded by a budget designed to support potentially world-leading studies, including research on induced pluripotent stem cells for regenerative medicine. [Science and Technology Panel, Japan]

Spain Turns to Science for Stimulus
Spain’s ministers recently approved the text of a new research law that aims to reward scientific talent and encourage entrepreneurship. [Science and Innovation Ministry, Spain]

Technical Assistance for RFA-RM-10-006: Advancing Regulatory Science through Novel Research and Science-Based Technologies (U01) (NOT-RM-10-003) [National Institutes of Health, United States]

Modification: This Notice Modifies RFA-RM-09-019 (NOT-RM-10-004) [National Institutes of Health, United States]

Notice of a Change in the Next Receipt Date for the Center of Biomedical Research Excellence Program Announcement (PAR-09-079) (NOT-RR-10-005) [National Institutes of Health, United States]

Notice of Intent to Publish a Funding Opportunity for the Reissue of RFA-TW-08-002 the International Research Ethics Education and Curriculum Development Award (R25) (NOT-TW-10-326)
[National Institutes of Health, United States]

Collaborative Research for Molecular and Genomic Studies of Behavior in Animal Models (R01) (PA-10-125) [National Institutes of Health, United States]

Fiscal Year 2008 Annual Report: Innovative Technology Advancing Public Health [Food and Drug Administration, United States]


36th Annual Meeting of the European Group for Blood & Marrow Transplantation (EBMT)
March 21-24, 2010
Vienna, Austria

12th Biennial Canadian Blood and Marrow Transplant Group (CBMTG) Conference
April 7-10, 2010
Vancouver, Canada

American Association for Cancer Research (AACR) 101st Annual Meeting 2010
April 17-21, 2010
Washington, DC, United States

International Society for Stem Cell Research (ISSCR) 8th Annual Meeting
June 16-19, 2010
San Francisco, United States

XXXIst International Congress of the International Society of Blood Transfusion (ISBT) in joint cooperation with the 43rd Congress of the German Society for Transfusion Medicine and Immunohematology (DGTI)
June 26-July 1, 2010
Berlin, Germany

Society for Hematology and Stem Cells (ISEH) 2010 Meeting
September 15-18, 2010
Melbourne, Australia

American Association of Blood Banks (AABB) Annual Meeting 2010
October 9-12, 2010
Baltimore, United States

52nd American Society of Hematology (ASH) Annual Meeting and Exposition
December 4-7, 2010
Orlando, United States

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.

Visit here to post your career opportunities.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!


Learn more about Hematopoiesis News: Archives  |  Events  |  Subscribe  |  Contact Us